Overview of Абаджио
Quick Facts
| Property | Description |
|---|---|
| Active ingredient | Teriflunomide |
| Form | Oral tablet (Film-coated) |
| Pharmacological class | Immunomodulatory agent |
| General purpose | Disease-modifying regulation of immune activity |
| Origin | Synthetic (Metabolite of Leflunomide) |
What Type of Drug is Абаджио?
Абаджио is a synthetic, prescription-only medication utilized as a Disease-Modifying Drug (DMD), containing the active ingredient Teriflunomide. It is classified as an Immunomodulatory agent (Immunomodulator) because its core action is to selectively regulate aspects of the body's overactive immune system. The distinctive feature of Абаджио is its simple oral administration as an oral tablet (film-coated tablet), distinguishing it from numerous DMDs that necessitate injection or infusion.
Teriflunomide is chemically distinct in its origin; it is the principal active metabolite of Leflunomide, a chemically related drug traditionally used for rheumatoid arthritis. This DMD functions as a selective immunosuppressant, setting it apart from older, more generalized immunosuppressants by focusing its action on the specific immune cells driving the disease process. The drug's development has been clinically recognized for its ability to modify the course of the underlying neurological condition.
Teriflunomide: A Selective Approach to Immune Regulation
The general purpose of Абаджио is to modify the course of neurological disturbances by effectively controlling the underlying inflammatory processes. It achieves this by acting as an inhibitor of the enzyme Dihydroorotate Dehydrogenase (DHODH), a crucial step in pyrimidine synthesis, which is required for the DNA and RNA of rapidly dividing cells.
By inhibiting DHODH, the medicine specifically limits the rapid proliferation of T- and B-lymphocytes (key immune cells) that are responsible for inflammation and tissue damage in the central nervous system. This targeted, enzyme-specific blockade helps to provide a controlled anti-inflammatory effect aimed at reducing the frequency and severity of immune attacks, thereby intending to stabilize the patient's condition and help manage its progression.
Regulatory References
